Reviews/Anti CGRP Antibodies/Medication overuse headache treatment without detoxification
Medication Overuse · CGRP-MOH-01 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
This set of studies looks at whether drugs that block CGRP can clear medication overuse headache without first putting patients through a formal drug-withdrawal (detox) programme. A large randomised trial of erenumab enrolled patients who were not detoxified and found that more of them came out of medication overuse on the drug than on placebo [16], and an earlier randomised subgroup pointed the same way [21]. A second antibody, eptinezumab, also beat placebo in overuse patients, though both groups in that trial were given a short education session as well [22]. The one study that directly set a detox group against a no-detox group found no clear difference between them, but it was small [13], and many routine-care reports show overuse resolving without any withdrawal step [5][4][34][14]. The panel judged the claim well supported but stopped short of the top tier because the only head-to-head detox comparison was underpowered and the strongest randomised evidence is specific to erenumab rather than the whole drug class.
A Phase 4 placebo-controlled trial reported medication overuse remission as its primary endpoint in non-detoxified chronic migraine patients, with 69.1% remission on erenumab 140 mg versus 52.6% on placebo (OR 2.01) [16]. A randomised subgroup analysis found greater reductions in monthly migraine and acute-medication days with erenumab in the medication-overuse group [21], and a Class I eptinezumab trial beat placebo on monthly migraine days (-6.9 vs -3.7) in chronic migraine with overuse [22]. The single direct comparison of detoxified (n=28) versus non-detoxified (n=83) patients found no significant between-group difference in overuse reversion or response (p=0.4788, p=0.8393) [13]. Real-world cohorts consistently record overuse resolving without a withdrawal protocol, for example 60 of 99 overuse patients no longer meeting the definition after six months [5], and overuse reversion in [4], [34] and [14]. The contested point: The evidence divides on whether the studies show the antibodies work without detox or show them to be equivalent to detox: the randomised trials [16][21] establish efficacy in non-detoxified patients but never test against a detox strategy, and the one study that does [13] is too small for its null result to prove equivalence. A second fault line is scope, since the Class I data are erenumab-specific [16][21] plus one eptinezumab-with-education trial [22], while galcanezumab and fremanezumab support is real-world only [5][6][15].
All 35 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Anti CGRP Antibodies, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The only design directly testing the 'without detoxification' clause, Pensato [13], is underpowered (28 detox vs 83 non-detox); its non-significant p-values (0.4788, 0.8393) are absence of evidence of difference, not evidence of equivalence.
The Class I/II RCTs [16][21] demonstrate efficacy in non-detoxified MOH patients but never compare against a detoxification strategy, so they support 'works without detox,' not 'as effective as detox.'
Where it remains uncertain. The only study directly comparing detox with no-detox found no difference but was underpowered (28 vs 83; p=0.4788, p=0.8393) [13], so it cannot show equivalence, and the strongest randomised evidence is erenumab-specific rather than class-wide [16][21].
Aleatory
With only 28 detoxified versus 83 non-detoxified patients, random variation alone could mask a true difference, so the non-significant p-values (0.4788, 0.8393) in [13] carry wide uncertainty.
Epistemic
No study in the corpus adequately compares an antibody-without-detox strategy against detox, so equivalence is untested rather than refuted [13].
Inferential
The randomised trials [16][21] test the antibody against placebo in non-detoxified patients, which supports 'works without detox' but not the stronger reading that it matches a detox strategy.
The load-bearing papers from a corpus of 35, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Real-world MOH reversion without a detox protocol
“After 3 months, 23 patients (46.9%) were not suffering from a MOH anymore.”
Panel auditInternal validity: low · scope of inference: Highly therapy-refractory migraineurs, two-thirds with MOH, on erenumab 70 mg.Key limitations: no control arm · short follow-up · detox status not stated
Real-world cohort: MO cessation without detox, 60.6% no longer met MO definition
“In real-life anti-CGRP MAbs are as effective in CM patients with MO as in patients without it and facilitate MO cessation.”
Panel auditInternal validity: medium · scope of inference: Real-life chronic migraine patients on erenumab or galcanezumab over 6 months.Key limitations: observational · no placebo · detox not controlled
Only direct detox vs non-detox comparison: no significant between-group difference
“Our results support the emerging evidence that anti-CGRP monoclonal antibodies may be effective in medication overuse headache patients irrespective of detoxification, yet further studies are needed to draw definitive conclusions.”
Panel auditInternal validity: medium · scope of inference: Chronic migraine with MOH and ≥28 analgesic days/month starting erenumab or galcanezumab.Key limitations: non-randomised allocation · small unequal groups · null may reflect low power
Reports reduced analgesic consumption but no explicit MOH resolution and no detoxification contrast, so the claim's direction is not determinable.
Panel auditInternal validity: low · scope of inference: Resistant chronic migraine patients on three anti-CGRP mAbs under a reimbursement program.Key limitations: no MOH remission outcome · no detox contrast · single-arm
4 of 35 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Strong and consistent, including randomised evidence of efficacy in non-detoxified MOH patients, but held below Established because the only head-to-head detox comparison is underpowered and the claim generalises beyond the antibodies with Class I support.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Powered head-to-head: antibody with versus without detox. The only direct comparison [13] was underpowered (28 vs 83) and its null result cannot prove equivalence, which is the exact clause the claim asserts. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A randomised, adequately powered non-inferiority trial allocating medication-overuse patients to an anti-CGRP antibody with structured detox versus the same antibody without detox, with overuse remission as the primary endpoint.
Open question: Is an anti-CGRP antibody without detoxification non-inferior to the same antibody with detoxification for achieving medication overuse remission? Why it is still open: The only direct comparison [13] was underpowered and reported non-significant differences (p=0.4788, p=0.8393), which is absence of evidence of difference rather than evidence of equivalence.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19